LIM kinase inhibitor: A novel pharmacological strategy in the treatment of mixed symptoms in mixed LUTS?

被引：0
作者：
Yu, Q. [1 ]
Cen, P. [1 ]
Lan, H. [1 ]
Zhou, X. [1 ]
Huang, R. [1 ]
Zeng, G. [1 ]
机构：
[1] Guangzhou Med Univ, Dept Urol, Affiliated Hosp 1, Guangzhou, Peoples R China
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A1013
引用
收藏
页码：S2109 / S2109
页数：1
相关论文
共 50 条
  • [21] Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor
    Loehn, Matthias
    Plettenburg, Oliver
    Ivashchenko, Yuri
    Kannt, Aimo
    Hofmeister, Armin
    Kadereit, Dieter
    Schaefer, Matthias
    Linz, Wolfgang
    Kohlmann, Markus
    Herbert, Jean-Marc
    Janiak, Philip
    O'Connor, Stephen E.
    Ruetten, Hartmut
    [J]. HYPERTENSION, 2009, 54 (03) : 676 - 683
  • [22] The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD
    Schwid, S
    Shoulson, I
    Marek, K
    Oakes, D
    Kieburtz, K
    Gorbold, E
    Fahn, S
    Goetz, C
    Rudolph, A
    Shinaman, A
    [J]. NEUROLOGY, 2004, 62 (02) : 330 - 332
  • [23] Pharmacological inhibition of Axl tyrosine kinase as a novel therapeutic strategy in hepatocellular carcinoma
    Pinato, David James
    Trousil, Sebastian
    Caley, Matthew
    Mauri, Francesco A.
    Aboagye, Eric
    Sharma, Rohini
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] In vitro and in vivo pharmacological study of EB-3D: a novel choline kinase inhibitor for breast cancer treatment
    Mariotto, Elena
    Bortolozzi, Roberta
    Ronca, Roberto
    Lopez-Cara, Luisa C.
    Accordi, Benedetta
    Serafin, Valentina
    Basso, Giuseppe
    Viola, Giampietro
    [J]. CANCER RESEARCH, 2016, 76
  • [25] Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis
    Azevedo, Erly G.
    Ribeiro, Raul R.
    da Silva, Sydnei M.
    Ferreira, Claudio S.
    de Souza, Ligia E.
    Ferreira, Adriel A. F.
    de Oliveira e Castro, Renata A.
    Demicheli, Cynthia
    Rezende, Simone A.
    Frezard, Frederic
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2014, 11 (10) : 1551 - 1560
  • [26] Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
    Harrison, Bryce A.
    Almstead, Zheng Y.
    Burgoon, Hugh
    Gardyan, Michael
    Goodwin, Nicole C.
    Healy, Jason
    Liu, Ying
    Mabon, Ross
    Marinelli, Brett
    Samala, Lakshman
    Zhang, Yulian
    Stouch, Terry R.
    Whitlock, N. Andrew
    Gopinathan, Suma
    McKnight, Beth
    Wang, Shuli
    Patel, Nita
    Wilson, Alan G. E.
    Hamman, Brian D.
    Rice, Dennis S.
    Rawlins, David B.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (01): : 84 - 88
  • [27] PHARMACOLOGICAL ACTIONS OF A NOVEL MIXED OPIATE AGONIST-ANTAGONIST - NALOXONE BENZOYLHYDRAZONE
    GISTRAK, MA
    PAUL, D
    HAHN, EF
    PASTERNAK, GW
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1989, 251 (02) : 469 - 476
  • [28] Mixed porokeratosis with a novel mevalonate kinase gene mutation: A case report
    Hong-Jun Xu
    Guang-Dong Wen
    [J]. World Journal of Clinical Cases, 2022, 10 (14) : 4528 - 4534
  • [29] Development of a novel composite inhibitor modified with proanthocyanidins and mixed with ammonium polyphosphate
    Xue, Di
    Hu, Xiangming
    Cheng, Weimin
    Yu, Xiaoxiao
    Wu, Mingyue
    Zhao, Yanyun
    Lu, Yi
    Pan, Rongkun
    Niu, Huiyong
    Hu, Shengyong
    [J]. ENERGY, 2020, 213 (213)
  • [30] Mixed porokeratosis with a novel mevalonate kinase gene mutation: A case report
    Xu, Hong-Jun
    Wen, Guang-Dong
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (14) : 4528 - 4534
12345